LGMN and Parkinson disease: To investigate whether C/EBPβ/AEP axis plays an essential role in the gut pathologies associated with PD, we treated young α-SNCA, α-SNCA/AEP−/− and α-SNCA/C/EBPβ+/− mice (1-month-old) with 2.5 mg/kg of rotenone or vehicle control (P.O., once a day) consecutively for 3 months.